Skip to main content

Advertisement

SpringerLink
Log in

Conservative treatment of Peyronie’s disease: a guide

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To review the literature on the topic, to suggest a common line of treatment applicable across a wide community of specialists, and to contribute in maintaining the high level of interest in this disease.

Methods

A comprehensive and exhaustive review of the literature was performed, identifying hundreds of articles on the topic.

Results

Peyronie’s disease is a condition that has been recognized, studied, and treated for centuries; despite this, if one excludes surgery in cases in which the deformity is stable, no clear treatment (or line of treatment) is available for complete relief of signs and symptoms. Treatment options were divided into local, oral, and injection therapy, and a wide variety of drugs, remedies, and options were identified.

Conclusions

Low-intensity extracorporeal shock wave therapy, vacuum therapy, penile traction therapy, phosphodiesterase type 5 inhibitors, hyaluronic acid, and collagenase of Clostridium histolyticum may be recommended only in specific contexts. Further studies on individual options or potential combinations are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De la Peyronie FG (1743) Sur quelques obstacles qui s’opposent a l’éjaculation naturelle de la semence. Mém Acad Roy Chir 1:318–333

    Google Scholar 

  2. Levine L, Burnett AL (2013) Standard operating procedures for Peyronie’s disease. J Sex Med 10:230–244

    Article  PubMed  Google Scholar 

  3. Chung E, Ralph D, Kagiouglu A, Garaffa G, Shamsodini A, Boivalacqua T, Glina S, Hakim L, Sadeghi-Nejad H, Broderick G (2016) Evidence-based management guidelines on Peyronie’s disease. J Sex Med 13:905–923

    Article  PubMed  Google Scholar 

  4. Dibenedetti DB, Nguyen D, Zografos Ziemiecki R, Zhou X (2011) A population based study on Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. https://doi.org/10.1155/2011/282503

    Article  PubMed  PubMed Central  Google Scholar 

  5. Pozzi E, Capogrosso P, Boeri L, Cazzaniga W, Matloob R, Ventimiglia E, Oreggia D, Schifano N, Candela L, Abbate C, Montorsi F, Salonia A (2021) Trends in reported male sexual dysfunction over the past decade: an evolving landscape. Int J Impot Res 33(6):596–602. https://doi.org/10.1038/s41443-020-0324-7. (Epub 2020 Jul 1)

    Article  PubMed  Google Scholar 

  6. Smith BH (1966) Peyronie’s disease. Am J Clin Pathol 45:670–678

    Article  CAS  PubMed  Google Scholar 

  7. Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W et al (1977) Impact of Peyronie’s disease on sexual and psychological functioning: qualitative findings in patients and controls. J Sex Med 2008(5):84

    Google Scholar 

  8. Gelbard M, Lindner A, Chvapil M et al (1983) Topical beta-aminopropionitrile in the treatment of Peyronie’s disease. J Urol 129:746

    Article  CAS  PubMed  Google Scholar 

  9. Riedl CR, Sternig P, Gallé G et al (2005) Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double blind prospective clinical study. Eur Urol 48:656–661

    Article  CAS  PubMed  Google Scholar 

  10. Twidwell J, Levine L (2016) Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo- controlled pilot study. Int J Impot Res 28(2):41

    Article  CAS  PubMed  Google Scholar 

  11. Martin DJ, Badwan K, Parker M, Mulhall JP (2002) Transdermal application of Verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 168:2483–2485

    Article  CAS  PubMed  Google Scholar 

  12. Fitch WP III, Easterling WJ, Talbert RL et al (2007) Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease – a placebo-controlled pilot study. J Sex Med 4(2):477–484

    Article  CAS  PubMed  Google Scholar 

  13. Di Stasi SM, Giannantoni A, Stephen RL et al (2004) A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 171(4):1605–1608

    Article  PubMed  Google Scholar 

  14. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W (2004) Extracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trials. J Urol 171(2):740–745

    Article  PubMed  Google Scholar 

  15. Hatzichristodoulou G et al (2013) Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo- controlled, prospective, randomized, single blind study. J Sex Med 10:2815–2821

    Article  PubMed  Google Scholar 

  16. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4

  17. Pietsch G, Anzeneder T, Bruckbauer H et al. Superficial radiation therapy in Peyronie’s disease: an effective and well-tolerated therapy. Adv Radiat Oncol. 2018;3(4):548–551. Published 2018 Aug 7

  18. Gontero P et al (2009) Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med 6:558–566

    Article  PubMed  Google Scholar 

  19. Ziegelmann M et al (2019) Outcomes of a novel penile traction device in men with Peyronie’s disease: a randomized, single-blind, controlled trial. J Urol 202:599

    Article  PubMed  Google Scholar 

  20. Schaeffer AJ, Burnett AL (2012) Nonsurgical interventions for Peyronie disease: 2011 update. J Androl 33(1):3–14. https://doi.org/10.2164/jandrol.110.010561. (Epub 2011 Feb 24. PMID: 21350241)

    Article  CAS  PubMed  Google Scholar 

  21. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF (2006) Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease. BJU Int 97(3):625–633. https://doi.org/10.1111/j.1464-410X.2006.05955.x. (PMID: 16469038)

    Article  CAS  PubMed  Google Scholar 

  22. Ilg MM, Stafford SJ, Mateus M, Bustin SA, Carpenter MJ, Muneer A, Bivalacqua TJ, Ralph DJ, Cellek S (2020) Phosphodiesterase type 5 inhibitors and selective estrogen receptor modulators can prevent but not reverse myofibroblast transformation in Peyronie’s disease. J Sex Med 17(10):1848–1864. https://doi.org/10.1016/j.jsxm.2020.06.022. (Epub 2020 Aug 5. PMID: 32771352)

    Article  CAS  PubMed  Google Scholar 

  23. Kadioglu A, Tefekli A, Köksal T, Usta M, Erol H (2000) Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 12(3):169–175. https://doi.org/10.1038/sj.ijir.3900519. (PMID: 11045911)

    Article  CAS  PubMed  Google Scholar 

  24. Safarinejad MR (2004) Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 16(3):238–243. https://doi.org/10.1038/sj.ijir.3901185. (PMID: 14973528)

    Article  CAS  PubMed  Google Scholar 

  25. Safarinejad MR (2010) Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res 22(5):298–309. https://doi.org/10.1038/ijir.2010.20. (Epub 2010 Aug 19. PMID: 20720560)

    Article  CAS  PubMed  Google Scholar 

  26. Bremer J (1983) Carnitine–metabolism and functions. Physiol Rev 63(4):1420–1480. https://doi.org/10.1152/physrev.1983.63.4.1420. (PMID: 6361812)

    Article  CAS  PubMed  Google Scholar 

  27. Biagiotti G, Cavallini G (2001) Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int 88(1):63–67. https://doi.org/10.1046/j.1464-410x.2001.02241.x. (PMID: 11446848)

    Article  CAS  PubMed  Google Scholar 

  28. Safarinejad MR, Hosseini SY, Kolahi AA (2007) Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized study. J Urol. 178(4 Pt 1):1398–1403; discussion 1403. https://doi.org/10.1016/j.juro.2007.05.162. Epub 2007 Aug 16. PMID: 17706714

  29. Safarinejad MR (2009) RETRACTED: efficacy and safety of omega-3 for treatment of early-stage Peyronie’s disease: a prospective, randomized, double-blind placebo-controlled study. J Sex Med 6(6):1743–1754. https://doi.org/10.1111/j.1743-6109.2009.01235.x. (Epub 2009 Apr 23. PMID: 19453924)

    Article  CAS  PubMed  Google Scholar 

  30. Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, Lin CS, Lue TF (2010) Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 7(6):2077–2085. https://doi.org/10.1111/j.1743-6109.2010.01790.x. (Epub 2010 Mar 30. PMID: 20367772; PMCID: PMC3543151)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, Schuppan D (2002) Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 50(2):241–247. https://doi.org/10.1136/gut.50.2.241. (PMID: 11788567; PMCID: PMC1773098)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Park TY, Jeong HG, Park JJ, Chae JY, Kim JW, Oh MM, Park HS, Kim JJ, du Moon G (2016) The efficacy of medical treatment of Peyronie’s disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor. World J Mens Health. 34(1):40–46. https://doi.org/10.5534/wjmh.2016.34.1.40. (Epub 2016 Apr 30. PMID: 27169128; PMCID: PMC4853769)

    Article  PubMed  PubMed Central  Google Scholar 

  33. Armand JP, Ribrag V, Harrousseau JL, Abrey L (2007) Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag 3(2):213–224. https://doi.org/10.2147/tcrm.2007.3.2.213. (PMID: 18360630; PMCID: PMC1936303)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR, Sporn MB, Baum M (1990) Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 62(3):405–409. https://doi.org/10.1038/bjc.1990.307. (PMID: 1698443; PMCID: PMC1971440)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA (1999) Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol 162(6):2003–2005. https://doi.org/10.1016/s0022-5347(05)68087-1. (PMID: 10569556)

    Article  CAS  PubMed  Google Scholar 

  36. Shindel AW, Bullock TL, Brandes S (2008) Urologist practice patterns in the management of Peyronie’s disease: a nationwide survey. J Sex Med 5(4):954–964. https://doi.org/10.1111/j.1743-6109.2007.00674.x. (Epub 2007 Nov 27. PMID: 18042214)

    Article  PubMed  Google Scholar 

  37. Levine LA, Goldman KE, Greenfield JM (2002) Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 168(2):621–626. https://doi.org/10.1016/s0022-5347(05)64691-5

    Article  CAS  PubMed  Google Scholar 

  38. Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2002) Peyronie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14(5):397–405. https://doi.org/10.1038/SJ.IJIR.3900874

    Article  CAS  PubMed  Google Scholar 

  39. Hellstrom WJG, Kendirci M, Matern R et al (2006) Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon α-2b for minimally invasive treatment for Peyronie’s disease. J Urol 176(1):394–398. https://doi.org/10.1016/S0022-5347(06)00517-9

    Article  CAS  PubMed  Google Scholar 

  40. Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJG (2013) Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease. J Urol 190(6):2194–2199. https://doi.org/10.1016/j.juro.2013.05.022

    Article  CAS  PubMed  Google Scholar 

  41. Stewart CA, Yafi FA, Knoedler M et al (2015) Intralesional injection of interferon-α2b improves penile curvature in men with Peyronie’s disease independent of plaque location. J Urol 194(6):1704–1707. https://doi.org/10.1016/j.juro.2015.06.096

    Article  CAS  PubMed  Google Scholar 

  42. Juncan AM, Moisă DG, Santini A et al (2021) Advantages of hyaluronic acid and its combination with other bioactive ingredients in cosmeceuticals. Molecules 26(15):4429. https://doi.org/10.3390/MOLECULES26154429

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Gennaro R, Barletta D, Paulis G (2015) Intralesional hyaluronic acid: an innovative treatment for Peyronie’s disease. Int Urol Nephrol 47(10):1595–1602. https://doi.org/10.1007/s11255-015-1074-1

    Article  CAS  PubMed  Google Scholar 

  44. Zucchi A, Costantini E, Cai T et al (2016) Intralesional injection of hyaluronic acid in patients affected with Peyronie’s disease: preliminary results from a prospective, multicenter, pilot study. Sex Med 4(2):e85–e90. https://doi.org/10.1016/j.esxm.2016.01.002

    Article  PubMed Central  Google Scholar 

  45. Cocci A, Di Maida F, Cito G et al (2020) Comparison of intralesional hyaluronic acid vs. verapamil for the treatment of acute phase Peyronie’s disease: a prospective, open-label non-randomized clinical study. World J Mens Health 38(2):1–6. https://doi.org/10.5534/wjmh.190108

    Article  Google Scholar 

  46. Muñoz-Rangel CA, Fernandez-Vivar E, Bañuelos-Gallo RA et al (2015) Minimally invasive therapy using intralesional onabotulinumtoxinA in Peyronie’s disease. Urol J 12(2):2105–2110. https://doi.org/10.22037/UJ.V12I2.2894

    Article  PubMed  Google Scholar 

  47. Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R (1998) Betamethasone versus placebo in Peyronie’s disease [Article in Italian]. Arch Ital Urol Androl 70(4):165–168. https://pubmed.ncbi.nlm.nih.gov/9823662/

  48. Alkandari MH, Touma N, Carrier S (2021) Platelet-rich plasma injections for erectile dysfunction and Peyronie’s disease: a systematic review of evidence. Sex Med Rev 10:341–352

    Article  PubMed  Google Scholar 

  49. Culha MG, Erkan E, Cay T, Yücetaş U (2019) The effect of platelet-rich plasma on Peyronie’s disease in rat model. Urol Int 102(2):218–223

    Article  PubMed  Google Scholar 

  50. Gelbard M et al (2011) Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190(1):199–207

    Article  Google Scholar 

  51. Lipshulz LI et al (2015) Clinical efficacy of collagenase chlostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double blind, randomized, placebo-controlled, phase III studies. BJU Int 116(4):650–656

    Article  Google Scholar 

  52. El-Khatib FM, Towe M, Yafi FA (2020) Management of Peyronie’s disease with collagenase Clostridium histolyticum in the acute phase. World J Urol 38(2):299–304. https://doi.org/10.1007/s00345-019-02791-x. (Epub 2019 May 15)

    Article  PubMed  Google Scholar 

  53. Masterson TA, Rezk A, Ramasamy R (2020) Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie’s disease: a review of the literature. World J Urol 38(2):279–285. https://doi.org/10.1007/s00345-019-02850-3. (Epub 2019 Jun 26)

    Article  CAS  PubMed  Google Scholar 

  54. Devine CJ, Somers KD, Jordan SG, Schlossberg SM (1997) Proposal: trauma as the cause of Peyronie’s disease. J Urol 157(1):285–290. https://doi.org/10.1016/s0022-5347(01)65361-8

    Article  PubMed  Google Scholar 

  55. Kramann R, DiRocco DP, Humphreys BD (2013) Understanding the origin, activation and regulation of matrix-producing myofibroblast for treatment of fibrotic disease. J Pathol 231(3):273–289. https://doi.org/10.1002/path.4253

    Article  CAS  PubMed  Google Scholar 

  56. Aber MR, Larsen S, Levine LA (2012) Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s disease. J Sex Med 9(1):288–295. https://doi.org/10.1111/j.1743-6109.2011.02519.x. (Epub 2011 Oct 24)

    Article  CAS  Google Scholar 

  57. Martinez Salamanca JI et al (2014) Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med 11(2):506–515. https://doi.org/10.1111/jsm.12400

    Article  PubMed  Google Scholar 

  58. Dalm V, Dik WA, Thio HB, van den Blink B, van Hagen PM, van Daele PL (2015) Fibrosing disorders: insight into pathogenesis and new treatment options. Ned Tjdschr Geneeskd 159:A8345

    Google Scholar 

  59. European Association of Urology Sexual and Reproductive Health Guidelines. https://uroweb.org/guidelines/sexual-and-reproductive-health

  60. Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, Sener NC, Nalbant I, Imamoglu MA (2014) Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci 183(3):449–453. https://doi.org/10.1007/s11845-013-1036-5. (Epub 2013 Nov 5. PMID: 24190613)

    Article  CAS  PubMed  Google Scholar 

  61. Chung E, Deyoung L, Brock GB (2011) The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med 8(5):1472–1477. https://doi.org/10.1111/j.1743-6109.2011.02217.x. (Epub 2011 Feb 16. PMID: 21324095)

    Article  CAS  PubMed  Google Scholar 

  62. Salonia A, Bettocchi C, Carvalho J et al (2022) (EAU Sexual and Reproductive Health Guidelines Panel). European Association of Urology Sexual and Reproductive Health Guidelines; EAU Guidelines. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2022_2022-03-29-084141_megw.pdf

  63. Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, Khera M, Kirkby E, McVary KT, Miner MM, Nelson CJ, Sadeghi-Nejad H, Seftel AD, Shindel AW, Burnett AL, American Urological Association Education and Research, Inc. (2015) Peyronie’s disease: AUA guideline. J Urol 194(3):745–753. https://doi.org/10.1016/j.juro.2015.05.098. (Epub 2015 Jun 9. PMID: 26066402; PMCID: PMC5027990)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Uro-Andrology Department, Casa di Cura Villa Maria, Via delle Melette 22, 35138, Padua, Italy

    Marco Cosentino

  2. Department of Urology and Organ Transplantation, Università di Foggia, Foggia, Italy

    Michele Di Nauta, Anna Ricapito & Carlo Bettocchi

  3. Department of Urology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

    Luca Boeri, Gianpaolo Lucignani, Franco Gadda & Emanuele Montanari

  4. Urology Clinic, Department of Surgical, Oncological and Gastroenterological Sciences, Padova University, Padua, Italy

    Giordana Ferraioli, Massimo Iafrate, Mariangela Mancini & Fabrizio Dal Moro

  5. Andrology Department, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain

    Eduard Ruiz-Castañe

  6. Department of Urology, Ioannina University School of Medicine, Ioannina, Greece

    Nikolaos Sofikitis

Authors
  1. Marco Cosentino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michele Di Nauta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Boeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giordana Ferraioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gianpaolo Lucignani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anna Ricapito
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Franco Gadda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Massimo Iafrate
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mariangela Mancini
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fabrizio Dal Moro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eduard Ruiz-Castañe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Carlo Bettocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Emanuele Montanari
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Nikolaos Sofikitis
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Cosentino Marco contributed to project development, drafting manuscript, and editing. Di Nauta Michele, Boeri Luca, Ferraioli Giordana, Lucignani Gianpaolo, Ricapito Anna, and Iafrate Massimo were involved in drafting manuscript and data collection. Gadda Franco was involved in drafting manuscript. Mancini Mariangela contributed to drafting manuscript and supervision. Dal Moro Fabrizio, Ruiz-Castañe Eduard, Bettocchi Carlo, Montanari Emanuele, and Sofikitis Nikolaos performed supervision and editing.

Corresponding author

Correspondence to Marco Cosentino.

Ethics declarations

Conflict of interest

The authors have no disclosures or conflicts of interest to declare.

Research involving human participants and/or animals

None.

Informed consent

No need.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cosentino, M., Di Nauta, M., Boeri, L. et al. Conservative treatment of Peyronie’s disease: a guide. World J Urol 42, 317 (2024). https://doi.org/10.1007/s00345-024-04975-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00345-024-04975-6

Keywords

Search

Navigation